Mechanisms of relapse prevention in schizophrenia

Pharmacopsychiatry

Volumn 37, Issue SUPPL. 2, 2004, Pages

  Müller, Norbert ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CYTOKINE; NEUROLEPTIC AGENT;

ADRENERGIC SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CHRONIC DISEASE; COGNITIVE DEFECT; CONFERENCE PAPER; CYTOKINE RELEASE; DISEASE COURSE; DISEASE MARKER; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG WITHDRAWAL; EMOTION; HUMAN; IMMUNITY; INFECTION; INFLAMMATION; LIFE EVENT; MAINTENANCE THERAPY; MENTAL STRESS; METHODOLOGY; NEGATIVE SYNDROME; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; RELAPSE; REMISSION; RISK FACTOR; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SHORT COURSE THERAPY; SOCIAL ASPECT; SOCIAL DISABILITY;

BIOLOGICAL MARKERS; HUMANS; INFECTION; INTERLEUKINS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS;

EID: 9644288287     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832668     Document Type: Conference Paper

References (44)

1. American Psychiatric Association. Practise guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 (Suppl 4): S1S63
2. Angrist B, Peselow E, Rotrosen J, Gershon S. Relationships between responses to dopamine agonists, psychopathology, neuroleptic treatment response, and need for neuroleptic maintenance in schizophrenic subjects. Rec Adv Neuropsychopharmacol Adv Biosci 1981; 31: 49-54
3. Bailer J, Rist F, Brauer W, Rey ER. Patient rejection scale: correlations with symptoms, social disability and number of re-hospitalizations. Eur Arch Psychiatry Clin Neurosci 1994; 244: 45-48
4. Bebbington P, Kuipers L. The predictive utility of expressed emotions in schizophrenia: an aggregate analysis. Psychol Med 1994; 24: 707-718
5. Bosveld-van Haandel LJM, Slooff CJ, van den Bosch RJ. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. Acta Psychiatr Scand 2001; 103: 335-346
6. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22
7. Davidson M, Keefe RSE, Mohs R, Siever LJ, Losonczy MF, Horvarth TB, Davis KL. L-dopa challenge and relapse in schizophrenia. Am J Psychiatry 1987; 144: 934-938
8. Davis JM, Mentalon L, Watanabe MD. Depot antipsychotic drugs: place in therapy. Drugs 1994; 47: 741-773
9. Docherty JP, van Kammen DP, Siris SG, Marder ST. Stages of onset of schizophrenic psychoses. Am J Psychiatry 1978; 135: 420-426
10. Doering S, Müller E, Köpcke W, Pietzcker A, Gaebel W, Linden M, Müller P, Müller-Spahn F, Tegeler J, Schüssler G. Predictors of relapse and re-hospitalization in schizophrenia and schizoaffective disorder. Schizophrenia Bull 1998; 24: 87-98
11. Dutch Schizophrenia Foundation. Consensus document. The Netherlands: Schizophrenia Foundation, 1996
12. Gaebel W, Falkai P (eds.) Praxisleitlinien in Psychiatrie und Psychotherapie. Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff-Verlag, 1998
13. Gattaz WF, Abrahao AL, Foccacia R. Childhood meningitis, brain maturation and the risk of psychosis. Eur Arch Psychiatry Clin Neurosci, 2003 (in press)
14. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000; 321: 1371-1376
15. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option? J Clin Psychiatry 1992; 53: 426-433
16. Hogarty GE. Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 1993; 54 (Suppl 3): 18-23
17. Hogarty GE, Schooler NR, Ulrich RF, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analysis of a two-year controlled study of fluphenazine-clecanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979; 36: 1283-1294
18. Kelley ME, Yao JK, van Kammen DP. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in Schizophrenia. Neuropsychopharmacol 1999; 20: 603-611
19. Kissling W (ed). Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin, NY: Springer Verlag, 1991
20. Kissling W, Kane JM, Barnes TR, Dencker K, Fleischhacker WW, Goldstein JM, Johnsom DAW, Marder SR, Müller-Spahn F, Tegeler J, Wilstedt B, Woggon B. Guidelines for neuroleptic relapse prevention in schizophrenia: towards consensus view. in: Kissling W (ed). Guidelines for neuroleptic relapse prevention in schizophrenia Berlin, NY: Springer Verlag, 1991: pp 155-163
21. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-1222
22. Lieberman JA, Kane JM, Gadaletta D. Methylphenidate challenge tests and course of schizophrenia. Psychopharmacol Bull 1985; 21: 123-129
23. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JMJ, Bilder R. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57 (Suppl 9): 5-9
24. McEvoy JP, Scheifler PL, Frances A (eds). The expert consensus guideline series. Treatment of schizophrenia 1999. J Clin Psychiatry 1999; 60: (Suppl 11)
25. Müller N. Neuroimmunology of schizophrenia. In: D'Haenen H, den Boer JA, Willner P (eds). Biol Psychiatry J Wiley & Sons, 2002: pp 613-623
26. Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine-network in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 1-33
27. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokkullu S, Krampe K, Ulmschneider M, Möller H-J, Schwarz M. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029-1034
28. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller H-J, Gruber R, Riedel M. COX-2 Inhibition as Treatment Approach in Schizophrenia: Immunological Considerations and Clinical Effects of Celecoxib add-on Therapy. Eur Arch Psychiatry Clin Neurosci 2004; 254: 14-22
29. Müller-Spahn F. Neuroendokrinologie und Schizophrenieforschung. Berlin, NY: Springer Verlag, 1989
30. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis JA, Kelley MD, Yao JK, Peters JF. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995; 152: 1291-1297
31. Nuechterlein KH, Dawson ME, Ventura J, Gitlin M, Subotnik KL, Snyder KS, Mintz J, Bartzokis G. The vulnerability/stress model of schizophrenic relapse: alomgitudinal study. Acta Psychiat Scand 1994; (Suppl 382): 58-64
32. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158: 266-269
33. Rantakallio P, Jones P, Moring J, Von Wendt L. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: a 28-year follow-up. Int J Epidemiol 1997; 26: 837-843
34. Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247
35. Sartorius N, Gulbinat W, Harrison G, Laska G, Siegel C. Long-term follow-up of schizophrenia in 16 countries: a description of the International Study of Schizophrenia conducted by the World Health Organisation. Soc Psychiatry Psychiatr Epidemiol 1996; 31: 249-258
36. Schaub A. Relapse and coping behavior in schizophrenia. Schizophrenia Res 1994; 11: 188
37. Schaub A. Coping-Forschung und bewältigungsorientierte Therapien bei schizophrenen Störungen. In: Bäuml J, Pitschl-Walz G (Hrsg). Pschoedukation bei schizophrenen Erkrankungen. Schattauer Stuttgart, NY: 2003: pp 173-203
38. Szymanski HV, Simon JC, Gutterman N. Recovery from schizophrenic psychosis. Am J Psychiatry 1983; 140: 335-338
39. van Kammen DP, Kelley MD, Gurklis JA, Gilbertson MK, Yao JK, Peters JF. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. Arch Gen Psychiatry 1995; 52: 673-678
40. van Kammen DP, Kelley MD, Gurklis JA, Gilbertson MK, Yao JK, Codray R, Peters JF. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients. Neuropsychopharmacol 1996; 14: 603-611
41. van Kammen DP, Peters JF, van Kammen WB, Nugent A, Goetz KL, Yao JK, Linnoila M. CSF Norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol Psychiatry, 1989: 179-188
42. Wiersma D, Nienhuis FJ, Sloof CJ, Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull 1998; 24: 75-85
43. Zhang-Wong J, Beiser M, Bean G, Iacono WG. Five-year course of schizophreniform disorder. Psychiatry Res 1995; 59: 109-117
44. Zubin J, Steinhauer SR, Day R, van Kammen DP. Schizophrenia at the crossroads: A blueprint of the 80's. Compr Psychiatry 1985; 26: 217-240